Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 431-441

  Kashiwagi, Eiji ^a   Shiota, Masaki ^a   Yokomizo, Akira ^a   Itsumi, Momoe ^a   Inokuchi, Junichi ^a   Uchiumi, Takeshi ^b   Naito, Seiji ^a  

^a Department of Urology ^*  (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Androgen receptor; Aspirin; Castration resistant prostate cancer; Cyclooxygenase; EP3; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN RECEPTOR; N [(5 BROMO 2 METHOXYPHENYL)SULFONYL] 3 [2 (2 NAPHTHYLMETHYL)PHENYL]ACRYLAMIDE; PROSTAGLANDIN E RECEPTOR 3; PROSTATE SPECIFIC ANTIGEN; SULPROSTONE;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

ANDROGEN RECEPTOR; ASPIRIN; CASTRATION-RESISTANT PROSTATE CANCER; CYCLOOXYGENASE; EP3; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; ASPIRIN; CASTRATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RNA, MESSENGER;

EID: 84879473015     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0344     Document Type: Article

References (50)

1. Bennett A 1986 The production of prostanoids in human cancers, and their implications for tumor progression. Progress in Lipid Research 25 539-542. (doi:10.1016/0163-7827(86)90109-8)
2. Cha YI & DuBois RN 2007 NSAIDs and cancer prevention: targets downstream of COX-2. Annual Review of Medicine 58 239-252. (doi:10.1146/annurev. med.57.121304.131253)
3. Chan TA, Morin PJ, Vogelstein B & Kinzler KW 1998 Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. PNAS 95 681-686. (doi:10.1073/pnas.95.2.681)
4. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF & Hla T 2004 Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. PNAS 101 591-596. (doi:10.1073/pnas.2535911100)
5. Chaudry AA, Wahle K, McClinton S & Moffat L 1994 Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. International Journal of Cancer 57 176-180. (doi:10.1002/ijc.2910570208)
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2003 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
7. Cusimano A, Foder D, Lampiasi N, Azzolina A, Notarbartolo M, Giannitrapani L, D'Alessandro N, Montalto G & Cervello M 2009 Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma. Annals of the New York Academy of Sciences 1155 300-308. (doi:10.1111/j.1749-6632.2009.03701. x)
8. DeWitt DL 1999 Cox-2-selective inhibitors: the new super aspirins. Molecular Pharmacology 55 625-631.
9. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M & Mizokami A 2002 Cyclooxygenase 2 promotes prostate cancer progression. Prostate 53 232-240. (doi:10.1002/pros.10152)
10. Fulton AM, Ma X & Kundu N 2006 Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Research 66 9794-9797. (doi:10.1158/0008-5472. CAN-06-2067)
11. Grösch S, Maier TJ, Schiffmann S & Geisslinger G 2006 Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute 98 736-747. (doi:10.1093/jnci/djj206)
12. Gupta RA & DuBois RN 2001 Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Reviews. Cancer 1 11-21. (doi:10.1038/35094017)
13. Gupta S, Srivastava M, Ahmad N, Bostwick D & Mukhtar H 2000 Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42 73-78. (doi:10.1002/(SICI)1097-0045(20000101)42:1!73:: AID-PROS9O3.0.CO;2-G)
14. Harris R 2009 Cyclooxygenase-2 (Cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17 55-67. (doi:10.1007/s10787-009-8049-8)
15. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM & Chen CS 2000 The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. Journal of Biological Chemistry 275 11397-11403. (doi:10.1074/jbc.275. 15.11397)
16. Huang HF, Shu P, Murphy TF, Aisner S, Fitzhugh V & Jordan ML 2013 Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer. Molecular Cancer Research [in press]. (doi:10.1158/1541-7786.MCR-12-0464)
17. Hwang DH, Fung V & Dannenberg AJ 2002 National Cancer Institute workshop on chemopreventive properties of nonsteroidal antiinflammatory drugs: role of COX-dependent and-independent mechanisms. Neoplasia 4 91-97. (doi:10.1038/sj.neo.7900226)
18. 2 regulates tumor angiogenesis in prostate cancer. Cancer Research 68 7750-7759. (doi:10.1158/0008-5472.CAN-07-6689)
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T & Thun MJ 2008 Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 58 71-96. (doi:10.3322/CA.2007.0010)
20. Kashiwagi E, Izumi H, Yasuniwa Y, Baba R, Doi Y, Kidani A, Arao T, Nishio K, Naito S & Kohno K 2010 Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. Cancer Science 102 382-386. (doi:10.1111/j.1349-7006.2010.01784.x)
21. Katori M & Majima M 2000 Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflammation Research 49 367-392. (doi:10.1007/s000110050605)
22. Kung HJ & Evans CP 2009 Oncogenic activation of androgen receptor. Urologic Oncology 27 48-52. (doi:10.1016/j.urolonc.2008.06.002)
23. Lim JTE, Piazza GA, Han EKH, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ & Brendel K 1999 Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochemical Pharmacology 58 1097-1107. (doi:10.1016/S0006-2952 (99)00200-2)
24. Lim JTE, Piazza GA, Pamukcu R, Thompson WJ & Weinstein IB 2003 Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clinical Cancer Research 9 4972-4982.
25. Macias-Perez IM, Zent R, Carmosino M, Breyer MD, Breyer RM & Pozzi A 2008 Mouse EP3 α, β, and γ receptor variants reduce tumor cell proliferation and tumorigenesis In vivo. Journal of Biological Chemistry 283 12538-12545. (doi:10.1074/jbc.M800105200)
26. Majima M, Amano H & Hayashi I 2003 Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends in Pharmacological Sciences 24 524-529. (doi:10.1016/j.tips.2003.08.005)
27. Mizokami A, Yeh SY & Chang C 1994 Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Molecular Endocrinology 8 77-88. (doi:10.1210/me.8.1.77)
28. Norwood VF, Morham SG & Smithies O 2000 Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney International 58 2291-2300. (doi:10.1046/j.1523-1755.2000.00413.x)
29. Okumura T, Hayashi I, Ikezawa T, Yamanaka M, Takata T, Fujita Y, Saigenji K, Yamashina S & Majima M 2002 Cyclooxygenase-2 inhibitors attenuate increased blood pressure in renovascular hypertensive models, but not in deoxycorticosterone-salt hypertension. Hypertension Research 25 927-938. (doi:10.1291/hypres.25.927)
30. Pan Y, Zhang JS, Gazi MH & Young CYF 2003 The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiology, Biomarkers & Prevention 12 769-774.
31. Patel M, Subbaramaiah K, Du B, Chang M, Yang P, Newman R, Cordon-Cardo C, Thaler H & Dannenberg A 2005 Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clinical Cancer Research 11 1999-2007. (doi:10.1158/1078-0432.CCR-04-1877)
32. Pruthi R, Derksen J & Moore D 2004 A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU International 93 275-278. (doi:10.1111/j.1464-410X.2004.04601.x)
33. Rigas B, Goldman I & Levine L 1993 Altered eicosanoid levels in human colon cancer. Journal of Laboratory and Clinical Medicine 122 518-523.
34. Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S & Cristofanilli M 2010 Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer 116 2806-2814. (doi:10.1002/cncr.25167)
35. Scher HI & Sawyers CL 2005 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology 23 8253-8261. (doi:10.1200/JCO.2005.03.4777)
36. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, Coffey CS & Wheeler TM 2001 Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3 287-303. (doi:10.1038/sj.neo.7900166)
37. Sharon P, Ligumsky M, Rachmilewitz D & Zor U 1978 Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 75 638-640.
38. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A, Yokomizo A, Naito S & Kohno K 2008 Twist promotes tumor cell growth through YB-1 expression. Cancer Research 68 98-105. (doi:10.1158/0008-5472.CAN-07-2981)
39. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D & Fukunaka Y 2009a Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Research 69 3148-3156. (doi:10.1158/0008-5472.CAN-08-2334)
40. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T & Naito S 2009b Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 29 237-250. (doi:10.1038/onc.2009.322)
41. Shiota M, Yokomizo A & Naito T 2011 Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. Journal of Molecular Endocrinology 47 25-41. (doi:10.1530/JME-11-0018)
42. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S & Sugimura T 2004 Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53 1151-1158. (doi:10.1136/gut.2003.028787)
43. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ & Kantoff PW 2006 Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. Journal of Clinical Oncology 24 2723-2728. (doi:10.1200/JCO.2005.03.7804)
44. Subbaramaiah K & Dannenberg AJ 2003 Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends in Pharmacological Sciences 24 96-102. (doi:10.1016/S0165-6147(02)00043-3)
45. Tanji N, Kikugawa T & Yokoyama M 2000 Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and Bcl-2 protein expression. Anticancer Research 20 2313-2319.
46. Wang D & DuBois RN 2010 Eicosanoids and cancer. Nature Reviews. Cancer 10 181-193. (doi:10.1038/nrc2809)
47. 2-induced VEGF expression in prostate cancer cells. Proceedings of the American Association for Cancer Research 2005 178.
48. Wang P, Zhu F, Lee NH & Konstantopoulos K 2010 Shear-induced interleukin-6 synthesis in chondrocytes. Journal of Biological Chemistry 285 24793-24804. (doi:10.1074/jbc.M110.110320)
49. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T & Wada S 2000 Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89 589-596. (doi:10.1002/1097-0142(20000801)89:3!589::AID- CNCR14O3.0.CO;2-C)
50. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG & Chang C 2009 NF-{kappa} B regulates androgen receptor expression and prostate cancer growth. American Journal of Pathology 175 489-499. (doi:10.2353/ajpath.2009.080727) Technology